VRAX (Virax Biolabs Group) Capex-to-Revenue : 356.00 (As of Mar. 2025)

View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Virax Biolabs Group's Capital Expenditure for the six months ended in Mar. 2025 was $-0.36 Mil. Its Revenue for the six months ended in Mar. 2025 was $0.00 Mil.

Hence, Virax Biolabs Group's Capex-to-Revenue for the six months ended in Mar. 2025 was 356.00.

Virax Biolabs Group Capex-to-Revenue Historical Data

The historical data trend for Virax Biolabs Group's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group Capex-to-Revenue Chart

Virax Biolabs Group Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Capex-to-Revenue

Get a 7-Day Free Trial

19.78

7.46

100.67

Virax Biolabs Group Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24	Mar25
Capex-to-Revenue	Get a 7-Day Free Trial						-	9.20	5.70	49.60	356.00

Competitive Comparison of Virax Biolabs Group's Capex-to-Revenue

For the Biotechnology subindustry, Virax Biolabs Group's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Virax Biolabs Group's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Virax Biolabs Group's Capex-to-Revenue falls into.

Save Embed

;

Save Embed

;

Virax Biolabs Group Capex-to-Revenue Calculation

Virax Biolabs Group's Capex-to-Revenue for the fiscal year that ended in Mar. 2025 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-0.604)	/	0.006
	=	100.67

Virax Biolabs Group's Capex-to-Revenue for the quarter that ended in Mar. 2025 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-0.356)	/	0.001
	=	356.00

Virax Biolabs Group (NAS:VRAX) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Virax Biolabs Group Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Virax Biolabs Group's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Virax Biolabs Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » Capex-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Bo’Ness Road Newhouse, BioCity Glasgow, London, GBR, ML1 5UH

Website

https://www.viraxbiolabs.com

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.